Original Article

You have full text access to this OnlineOpen article

Ovarian cancer screening with annual transvaginal sonography

Findings of 25,000 women screened

  1. John R. van Nagell Jr MD1,†,‡,*,
  2. Paul D. DePriest MD1,
  3. Frederick R. Ueland MD1,
  4. Christopher P. DeSimone MD1,
  5. Amy L. Cooper MD1,
  6. J. Matt McDonald MD1,
  7. Edward J. Pavlik PhD1,
  8. Richard J. Kryscio PhD2

Article first published online: 20 MAR 2007

DOI: 10.1002/cncr.22594

Issue

Cancer

Cancer

Volume 109, Issue 9, pages 1887–1896, 1 May 2007

Additional Information

How to Cite

van Nagell, J. R., DePriest, P. D., Ueland, F. R., DeSimone, C. P., Cooper, A. L., McDonald, J. M., Pavlik, E. J. and Kryscio, R. J. (2007), Ovarian cancer screening with annual transvaginal sonography. Cancer, 109: 1887–1896. doi: 10.1002/cncr.22594

Author Information

  1. 1

    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, Kentucky

  2. 2

    Department of Statistics, University of Kentucky Chandler Medical Center-Markey Cancer Center, Lexington, Kentucky

  1. †

    John R. van Nagell, Jr is an American Cancer Society Professor of Clinical Oncology.

  2. ‡

    Fax: (859) 323-1018.

*Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of Kentucky Medical Center, 800 Rose Street, Lexington, KY 40536

Publication History

  1. Issue published online: 18 APR 2007
  2. Article first published online: 20 MAR 2007
  3. Manuscript Accepted: 16 JAN 2007
  4. Manuscript Revised: 5 JAN 2007
  5. Manuscript Received: 24 OCT 2006

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (118K)

REFERENCES

  • 1
    Jemal A,Murray T,Ward E, et al. Cancer statistics 2005. CA Cancer J Clin. 2005; 55: 10–30.
    Direct Link:
  • 2
    Ueland FR,DePriest P,DeSimone C, et al. The accuracy of examination under anesthesia and transvaginal sonography in evaluating ovarian size. Gynecol Oncol. 2005; 99: 400–403.
  • 3
    Young RC,Walton LA,Ellenberg SS. Adjuvant therapy in stage I and II epithelial ovarian cancer: results of two prospective randomized trials. N Engl J Med. 1990; 322: 1021–1027.
  • 4
    Ries LA,Kosary CL,Hankey BF, et al. SEER Cancer Statistics Review, 1973–1995. Bethesda, Md: National Cancer Institute; 1998.
  • 5
    Campbell S,Bhan V,Royston P, et al. Transabdominal ultrasound screening for early ovarian cancer. Br Med J. 1989; 299: 1363:1367.
  • 6
    van Nagell JR,Higgins RV,Donaldson ES, et al. Transvaginal sonography as a screening method for ovarian cancer: a report of the first 1000 cases screened. Cancer. 1990; 65: 573–577.
    Direct Link:
  • 7
    Jacobs IJ,Bridges J,Reynolds C, et al. Multimodal approach to screening for ovarian cancer. Lancet. 1988; 2: 268–271.
  • 8
    Bourne TH,Campbell S,Reynolds KM, et al. Screening for early familial ovarian cancer with transvaginal ultrasonography and colour blood flow imaging. Br Med J. 1993; 306: 1025–1029.
  • 9
    DePriest PD,Gallion HH,Pavilk EJ,Kryscio RK,van Nagell JR. Transvaginal sonography as a screening method for the detection of early ovarian cancer. Gynecol Oncol. 1997; 65: 408–414.
  • 10
    Jacobs I,Skates SJ,MacDonald N,Menon U,Rosenthal A,Prys Davies A. Outcome of a pilot randomised controlled trial of ovarian cancer screening. Lancet. 1999; 253: 1207–1210.
  • 11
    Sato S,Yokoyama Y,Sakamoto T, et al. Usefulness of mass screening for ovarian carcinoma using transvaginal ultrasonography. Cancer. 2000; 89: 582–588.
    Direct Link:
  • 12
    van Nagell JR,DePriest P,Reedy M, et al. The efficacy of transvaginal sonographic screening in asymptomatic women at risk for ovarian cancer. Gynecol Oncol. 2000; 77: 350–356.
  • 13
    Buys SS,Partridge E,Greene MH, et al. Ovarian cancer screening in the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol. 2005; 193: 1630–1639.
  • 14
    Pavlik EJ,DePriest PD,Gallion HH, et al. Ovarian volume related to age. Gynecol Oncol. 2000; 77: 410–412.
  • 15
    Ueland F,DePriest P,Pavlik E,Kryscio R,van Nagell JR. Preoperative differentiation of malignant from benign ovarian tumors: the efficacy of morphology indexing and Doppler flow sonography. Gynecol Oncol. 2003; 91: 46–50.
  • 16
    Pavlik EJ,van Nagell JR,DePriest PD, et al. Participation in transvaginal ovarian cancer screening: compliance, correlation factors, and costs. Gynecol Oncol. 1995; 57: 395–400.
  • 17
    Pavlik EJ,Johnson TL,DePriest PD,Andrykowski MA,Kryscio RJ,van Nagell JR. Continuing participation supports ultrasound screening for ovarian cancer. Ultrasound Obstet Gynecol. 2000; 15: 354–364.
    Direct Link:
  • 18
    Higgins RV,van Nagell JR,Woods CH,Thompson EA,Kryscio RJ. Interobserver variation in ovarian measurements using transvaginal sonography. Gynecol Oncol. 1990; 39: 69–71.
  • 19
    Prorok PC. Evaluation of screening program for the early detection of cancer. Natl Cancer Inst Stat Textbk Monogr. 1984; 51: 267–328.
  • 20
    Hulka BS. Cancer screening: degrees of proof and practical application. Cancer. 1989; 62: 1776–1789.
    Direct Link:
  • 21
    Sassone M,Timor-Tritsch I,Artner A,Westhoff C,Warren WB. Transvaginal sonographic characterization of ovarian disease: evaluation of a new scoring system to predict ovarian malignancy. Obstet Gynecol. 1991; 78: 70–76.
  • 22
    DePriest PD,Shenson D,Fried A, et al. A morphology index based on sonographic findings in ovarian cancer. Gynecol Oncol. 1993; 51: 7–11.
  • 23
    Bailey CL,Ueland FR,Land GL, et al. Malignant potential of small cystic ovarian tumors in postmenopausal women. Gynecol Oncol. 1998; 69: 3–7.
  • 24
    Modesitt SC,Pavlik EJ,Ueland FR, et al. Risk of malignancy in unilocular ovarian cystic tumors less than 10 cm in diameter. Obstet Gynecol. 2003; 102: 594–599.
  • 25
    Malkasian G,Knapp R,Lavin P, et al. Preoperative evaluation of serum Ca-125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol. 1988; 159: 341–346.
  • 26
    Maggino T,Gadduci A,Daddario V, et al. Prospective multicenter study on Ca-125 in postmenopausal pelvic masses. Gynecol Oncol. 1994; 54: 117–123.
  • 27
    Baron A,Boardman C,Lafky J, et al. Soluble epidermal growth factor receptor and cancer antigen 125 as screening and diagnostic tests for epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005; 14: 1–13.
  • 28
    Jacobs IJ,Skates S,Davies AP, et al. Risk of diagnosis of ovarian cancer after raised serum Ca-125 concentration: a prospective cohort study. Br Med J. 1996; 313: 1355–1358.
  • 29
    Humphrey LL,Helfand M,Benjamin KS, et al. Breast cancer screening: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002; 137: 347–360.
  • 30
    Hartmann KE,Hall SA,Nanda K, et al. Screening for Cervical Cancer. Systematic Evidence Review No. 25. Rockville, Md: Agency for Healthcare Research and Quality; 2002.
  • 31
    Maribs Study Group. Screening with magnetic resonance imaging and mammography of a UK population at high familial risk of breast cancer: a prospective multicentre cohort study. Lancet. 2005; 365: 1769–1778.
  • 32
    Skates S,Manon U,MacDonald N, et al. Calculation of the risk of ovarian cancer from serial Ca-125 values for preclinical detection in postmenopausal women. J Clin Oncol. 2003; 21: 206–210.
  • 33
    Urban N,Drescher C,Etzioni R,Colby C. Use of a stochastic simulation model to identify an efficient protocol for ovarian cancer screening. Control Clin Trials. 1997; 18: 251–270.
  • 34
    Petricoin EF,Ardekani AM,Hitt BA, et al. Use of proteomic patterns in serum to identify ovarian cancer. Lancet. 2002; 359: 572–577.
  • 35
    Ransohoff D. Lessons from controversy: ovarian cancer screening and serum proteomics. J Natl Cancer Inst. 2005; 97: 315–319.
  • 36
    Armstrong DK,Bundy B,Wenzel L, et al. Phase III randomized trial of intravenous cisplatin and paclitaxel versus an intensive regimen of intravenous paclitaxel, and intraperitoneal paclitaxel in stage III ovarian cancer: a Gynecologic Oncology Group study. N Engl J Med. 2006; 354: 34–43.
View Full Article (HTML) Get PDF (118K)